Pilot study to review alternative assessments of adequacy of dialysis in patients with kidney failure

Pilot study to review alternative assessments of adequacy of dialysis in patients with kidney failure: a prospective cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70556765

Enrollment

100

Registered

2013-11-01

Start date

2013-10-01

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal and cardiac Urological and Genital Diseases

Interventions

Conventional markers of dialysis adequacy and in addition measurement of skin autofluorescence, plasma endotoxin and modified albumin. Cardiovascular assessments: blood pressure (pulse

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Treated for chronic kidney failure 2. Ability to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent 2. Aged below 18 years

Design outcomes

Primary

Measure	Time frame
To determine the practicability of measuring skin autofluorescence, endotoxin and modified albumin in the study population and whether these factors correlate with conventional markers of dialysis adequacy. Blood samples will be taken at entry into the study and then at 12 months to determine concentrations of endotoxin and modified albumin. Similarly blood pressure, ECG and skin autofluorescence will be measured at study entry and then at 12 months. Measurements of arterial size will be made once at study entry.	—

Measure

Time frame

To determine the practicability of measuring skin autofluorescence, endotoxin and modified albumin in the study population and whether these factors correlate with conventional markers of dialysis adequacy. Blood samples will be taken at entry into the study and then at 12 months to determine concentrations of endotoxin and modified albumin. Similarly blood pressure, ECG and skin autofluorescence will be measured at study entry and then at 12 months. Measurements of arterial size will be made once at study entry.

—

Secondary

Measure	Time frame
To determine whether skin autofluorescence, endotoxin and modified albumin correlate with cardiovascular risk factors	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026